Table 4 Factors influencing height gain in GnRHa + GH treated girls at GnRHa treatment.

From: Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty

 

At GnRHa treatment

At 1 year after treatment

At end of treatment

Coefficient (β)

Ρ

Coefficient (β)

Ρ

Coefficient (β)

Ρ

TH (cm)

0.361

0.099

    

CA (year)

− 0.128

0.571

− 0.125

0.581

0.264

0.235

BA (year)

0.693

 < 0.001

0.632

0.002

0.155

0.539

BA–CA

0.600

 < 0.001

0.484

0.023

0.141

0.576

Height

− 0.121

0.590

0.006

0.979

0.386

0.076

Height SDS

− 0.181

0.858

0.061

0.786

0.197

0.381

Weight

0.060

0.792

0.112

0.619

0.407

0.060

Weight SDS

0.121

0.592

0.157

0.485

0.304

0.169

BMI (kg/m2)

0.154

0.495

0.152

0.501

0.315

0.153

BMI SDS

0.168

0.456

0.172

0.445

0.274

0.216

PAH (cm)

− 0.775

 < 0.001

− 0.295

0.183

0.325

0.140

PAH SDS

− 0.769

 < 0.001

− 0.302

0.172

0.333

0.130

LH (mIU/mL)

− 0.375

0.085

− 0.533

0.023

− 0.029

0.911

FSH (mIU/mL)

− 0.128

0.571

− 0.485

0.041

− 0.397

0.114

E2 (pg/mL)

0.216

0.373

0.123

0.627

0.277

0.299

Dose of GH

    

− 0.338

0.124

Duration of GH treatment

    

0.371

0.090

  1. GnRHa Gonadotropin-releasing hormone agonist, GH Growth hormone, TH Target height, CA Chronological age, BA Bone age, SDS Standard deviation score, BMI body Mass index, PAH Predicted adult height-calculated with advanced table of baley–Pinneau (BP) method; luthenizing hormone, FSH Follicular stimulating hormone; E2, estrogen.
Back to article page